A Portfolio Model of Drug Development for Tuberculosis
- 3 March 2006
- journal article
- policy forum
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 311 (5765) , 1246-1247
- https://doi.org/10.1126/science.1119299
Abstract
Because of inadequate funding and the lack of promising drugs, no new antituberculosis drugs are likely to become available before 2010.Keywords
This publication has 7 references indexed in Scilit:
- Health and economic benefits of an accelerated program of research to combat global infectious diseasesCMAJ : Canadian Medical Association Journal, 2004
- The Growing Burden of TuberculosisArchives of internal medicine (1960), 2003
- How Bayer Makes Decisions to Develop New DrugsInterfaces, 2002
- Multidrug-resistant tuberculosisInfectious Disease Clinics of North America, 2002
- Robert G Ridley—realising the potential of public-private partnershipsThe Lancet Infectious Diseases, 2002
- Multidrug-resistant tuberculosis—can the tide be turned?The Lancet Infectious Diseases, 2001
- Project Portfolio Management: A Powerful Strategic Weapon in Pharmaceutical Drug DevelopmentDrug Information Journal, 1998